A low float, strong catalyst, and big volume caused SLS (Sellas Life Sciences) to run hard and trap short sellers yesterday.
SLS (Sellas Life Sciences) flew nearly 200% yesterday after a price target increase and positive results from their breast cancer drug’s phase 2 trials. It pumped on nearly 18 million shares in volume, and stayed strong into close. When paired with their low float and short crowded situation, I bought it in the day two premarket looking for the squeeze. The squeeze came right on time and resulted in a $1,300 gain.